TAISHO PHARMACEUTICAL HOLDINGS
> News Releases(2015)
Ceremony Commemorating 20th Anniversary of Taurine Joint Venture
Acquisition of Manufacturing and Marketing Approval in Japan for the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA® Tape(Taisho Pharmaceutical Holdings)
Notice Concerning Announcement of Results of Phase 3 Clinical Trials of TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen at the Annual Meeting of the Japanese Clinical Orthopaedic Association
TAISHO AND ABLYNX SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFα NANOBODY (OZORALIZUMAB) IN JAPAN
Notice of Changes in Board Members and Personnel of the Company and Its Consolidated Subsidiary(Taisho Pharmaceutical Holdings)
Signing of Domestic Sales Rights Licensing Agreement Regarding TT-063 Anti-inflammatory Analgesic Patch Formulation Containing S-Flurbiprofen(Taisho Pharmaceutical Holdings)
Results of Phase III Clinical Trial of Ibandronate Sodium Hydrate Oral Formulation, Bisphosphonate Antiresorptive Agent, in Japanese Patients with Osteoporosis Presented
New Drug Application Filed for Ibandronate Sodium Hydrate Oral Agent, Bisphosphonate Antiresorptive Agent
Adobe Reader is required to view these files.
is distributed free of charge by Adobe Systems Incorporated.
Social and Environment Activities
Terms and Privacy